GNE-140 racemate (Standard)
GNE-140 racemate (Standard) is the analytical standard of GNE-140 racemate (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and also a tautomer of GNE-140 (HY-118241). GNE-140 racemate is an orally active lactate dehydrogenase inhibitor, with an IC50 of 3 nM against human LDHA and an IC50 of 5 nM against LDHB. GNE-140 racemate reduces the phosphorylation level and total protein expression of p38 MAPK, and inhibits EGF-induced AKT phosphorylation. GNE-140 racemate decreases lactate production, regulates glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, increases extracellular pH, inhibits cell proliferation, migration and invasion, and induces caspase-3 activation and ROS accumulation. GNE-140 racemate can be used in research related to breast cancer, cystic fibrosis and pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 1802977-61-2
- Formula: C25H23ClN2O3S2
- Molecular Weight:499.04
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1802977-61-2
-
Molecular Weight 499.04
-
Formula C25H23ClN2O3S2
-
SMILES
O=C(C1SC2=CC=CC=C2Cl)NC(C3=CSC=C3)(C4=CC=C(N5CCOCC5)C=C4)CC1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Khajah MA, et al. The effect of lactate dehydrogenase inhibitors on proliferation, motility and invasion of breast cancer cells highlights a new role for lactate. Molecular medicine reports. 2024 Jan;29(1):12. [Content Brief]
[2]. Valdivieso ÁG, et al. Impairment of CFTR activity in cultured epithelial cells upregulates the expression and activity of LDH resulting in lactic acid hypersecretion. Cellular and molecular life sciences : CMLS. 2019 Apr;76(8):1579-1593. [Content Brief]
[3]. Boudreau A, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature chemical biology. 2016 Oct;12(10):779-86. [Content Brief]
[4]. Ji JJ, et al. Kallistatin/Serpina3c inhibits cardiac fibrosis after myocardial infarction by regulating glycolysis via Nr4a1 activation. Biochimica et biophysica acta. Molecular basis of disease. 2022 Sep 01;1868(9):166441. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GNE-140 racemate (Standard) Related Classifications
HY-100742R Related Classifications
Powered by Bioz